Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma Plc LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 48.00p 46.00p 50.00p 48.00p 48.00p 48.00p 100 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -24.1 -18.9 - 50

Verona Pharma Share Discussion Threads

Showing 12801 to 12820 of 12825 messages
Chat Pages: 513  512  511  510  509  508  507  506  505  504  503  502  Older
DateSubjectAuthorDiscuss
14/10/2019
21:28
Are you still out there Timbo? The thread has lost momentum, unfortunately just like the company. News should start coming through soon regarding part one of MDI.
digger18
09/8/2019
09:55
Director Buy - Chairman buying 60000 can't be a bad sign
shearluc
06/8/2019
13:15
...and low and behold it falls again.... no surprize here then..... jam tommorrow as always....
haff1
05/8/2019
11:55
Some but not astounding progress....we have so must share price ground to be made up...this represents a very modest response imho...
haff1
05/8/2019
08:19
52 week low will do a good run off this rns
shanur90
30/7/2019
23:14
By the time we get the update someone might wish to ask what JAk thinks of the share price and if the drug is all he reckons as no sign of Significant shareholder value. If so then in which decade should we expect to see it. Why do they reward themselves disproportionately to the share price performance and is he aware no one is currently in profit yet he has continued to recruit at will and no further advancement to our lead drug if not only drug enisfenterine in my opinion. Does he see 40p as representing significant shareholder value. Please someone ask the question. Ask Jak at what share price level does this need to reach for them to call it a day and put shareholders out of their misery. All the above my opinion and can anyone post a Nasdaq share price and how that equates at the exchange rate to the share price on aim. Sorry for being slightly as have forgotten how many shares are worth the other as seems an age ago
shakin not stirred
30/7/2019
09:08
Nothing in todays press release to bring joy or excitement ... or even optimism to this drawn out process, that their caution suggests all you need know as an investor!
haff1
15/7/2019
09:56
Ive been in VRP for nearly 10 years now!! Foolish I know but its always been jam tomorrow for 10 years with a stedily decreasing share price and value...Its so depressing its untrue. I really cant afford to come out now and have to just hope ....though I stopped holding my breadth about 6 years ago ..... no 8 years ago....that it will come to market and have been worthwhile! Trouble is will it come to market before I pass away?
haff1
25/4/2019
23:11
Nice big awards again excessively ridiculous as have over seen a massive decline in share price yet share scheme totalling over 400 000 for JAK. Is that correct. LOL.
shakin not stirred
21/3/2019
13:28
RNS, interesting development..
bewise2
20/2/2019
07:41
https://www.investegate.co.uk/verona-pharma-plc--vrp-/gnw/verona-pharma-to-announce-financial-results-for-full-year-ended-december-31--2018-and-provide-clinical-development-update/20190220070000H5760/
mrshaungcm
21/1/2019
21:30
bewise WTF. Interested to see what they say next. The BOD certainly have a lot of explaining to do.
shakin not stirred
14/1/2019
17:28
Mr Market is not impressed Getting new drug compounds to market is very very difficult As well as very very expensive ... this share needs some good news fast Or previous happier days will soon be in the past Primary endpoints are very important ... hence the end. If you get my point
buywell3
14/1/2019
17:02
As I stated previously, I do not believe they are not pursuing the best strategy for the drug They should be either focusing on CF, or COPD exacerbations in an emergency room setting.
timbo003
14/1/2019
14:49
I did...my comment starts with"...overal"!
haff1
14/1/2019
11:23
Read the first bullet point in highlights.............
meijiman
14/1/2019
10:19
...overal looks like good news and the share price plummets?!
haff1
14/1/2019
09:29
Looks like 1.5 mg is the dose to progress. Although it was a fail on the primary I thought the most significant comment was; "The statistically significant reduction observed in residual volume for the ensifentrine 1.5 mg dose at certain time points, which is closely related to dyspnea or breathlessness, highlights the potential for ensifentrine to provide symptomatic improvement for patients with this progressive and debilitating disease." In addition it did achieve improvements in FEV1 but these were small and not statistically significant. A notably exception was the day 3 evening dose. They now have information to design the next trial to play to their strengths. If I had COPD and was offered it would I take it? Clearly the answer would be yes. I suspect that would be the general answer but would those with the purse strings pay for it?
pdt
11/1/2019
09:43
Vas, I doubt if the Vernalis directors had a lot of choice in the matter after their abject failure with the US venture. My guess is that Woodford just wanted to salvage what value he could, so insisted on the US closure and the sale of the company.
timbo003
10/1/2019
14:17
Tim Even under your interpretation the scenario you outline has an uncertain cash flow which from what I can see doesn't cover the reduced overheads and cash burn going forward. As I say, if the situation was as you point out and Vernalis was an 'absolute bargain', then it raises even more the question of why Vernalis's directors put the company up for sale in March 2018. Note also that the directors thought Ligand's bid was quite reasonable. So if things were expected to get better as you imply, why put the 'For Sale' sign up? And why no other bidders for such a bargain? Or was Ligand the only party to do due diligence on Vernalis? I imagine that David Ebsworth may have had a better view of things at Vernalis last March and may/may not have chatted informally to Vernalis - either before or after March 2018. I would also be very surprised if Vernalis themselves hadn't informally approached Verona about their intentions to sell bearing in mind the relationship between companies. So I do agree that there are questions to be asked bearing in mind that Vernalis held an interest in Verona's main asset when it put itself up for sale and that interest now finds itself in another party's hands. Which also raises the question, what are Ligand's intentions vis a vis their interest in Ensifentrine?
vasilis
Chat Pages: 513  512  511  510  509  508  507  506  505  504  503  502  Older
Your Recent History
LSE
VRP
Verona Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191016 10:25:35